Skip to main content

Onconetix Inc

For the period ended Mar 31, 2024. Filed May 20, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 20, 2024

ONCO$3.47-3.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Loss

Three Months Ended March 31, 2024Three Months Ended March 31, 2023
Revenue$700,433$—
Cost of revenue511,433—
Gross profit189,000—
Operating expenses
Selling, general and administrative3,736,4501,766,022
Research and development48,9641,082,237
Impairment of goodwill5,192,000—
Impairment of ENTADFI assets2,293,576—
Total operating expenses11,270,9902,848,259
Loss from operations(11,081,990)(2,848,259)
Other income (expense)
Interest expense – related party(225,063)—
Interest expense(187,993)—
Change in fair value of subscription agreement liability – related party226,400—
Other income28,507—
Change in fair value of contingent warrant liability—1,615
Total other income (expense)(158,149)1,615
Loss before income taxes(11,240,139)(2,846,644)
Income tax benefit121,567—
Net loss$(11,118,572)$(2,846,644)
Net loss per share, basic and diluted$(0.50)$(0.18)
Weighted average number of common shares outstanding, basic and diluted22,147,59815,910,415
Other comprehensive loss
Net loss$(11,118,572)$(2,846,644)
Foreign currency translation(4,991,144)—
Change in pension benefit obligation154,678—
Total comprehensive loss$(15,955,038)$(2,846,644)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.